Hot Topics in Cystic Fibrosis Podcast Series

INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS. The first CFTR modulator became available on the NHS in December 2016 and was made available for around 5% of pwCF. In 2022, around 90% of pwCF in the UK are suitable for CFTR modulator therapy. Whilst there is no doubt CFTR modulators have positively and dramatically altered the disease pathway of cystic fibrosis, there remains a level of uncertainty around how to manage the changing clinical picture of cystic fibrosis alongside these transformational medicines. This podcast series is designed to discuss some of the challenges of ‘Life alongside CFTR modulators.’ Date of Prep: January 2024 | IE-CHI-2300057